{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0030154",
      "entity_text" : "differentiation",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:446013",
      "entity_text" : "FDA",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "We also utilize this in vitro system to assess the therapeutic effects of Niclosamide (NIC), an FDA approved anthelminthic recently identified in an anti-ZIKV drug screen, and found that it reduces ZIKV production, partially restores differentiation, and prevents apoptosis in hiNSCs.",
  "reading_complete" : "2020-08-04T10:39:55Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T10:38:13Z",
  "trigger" : "restores",
  "evidence" : [ "FDA-approved anthelminthic recently identified in an anti-ZIKV drug screen, and found that it reduces ZIKV production, partially restores differentiation" ],
  "pmc_id" : "5829514",
  "score" : 0
}